copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Homepage - GRAIL GRAIL is a healthcare company innovating to solve healthcare’s most important challenges Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable
Careers - GRAIL Everything we do is guided by our mission to detect cancer early, when it can be cured We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched And as we grow, we’re looking for people who will increase the impact we can make on the world
Clinical Studies - GRAIL GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Our clinical study program We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection
Multi-cancer early detection - GRAIL The Galleri test was developed, and its performance characteristics were determined by GRAIL The Galleri test has not been cleared or approved by the U S Food and Drug Administration GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results MENLO PARK, Calif — Feb 20, 2025 — GRAIL, Inc (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates
GRAIL to Present New Data on Galleri® and its Methylation Platform at . . . GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
GRAIL to Announce Fourth Quarter 2024 Financial Results GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
Leadership Team - GRAIL To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world Our leadership team strives to push the boundaries of what is possible to achieve our bold mission
GRAIL and Quest Diagnostics Provide GRAIL’s Galleri® Multi-Cancer Early . . . GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
GRAIL Reports First Quarter 2025 Financial Results GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages